Serono
1511771
223908775
2008-07-06T13:26:19Z
SmackBot
433328
Date the maintenance tags or general fixes
{{Merge|Merck Serono|date=July 2008}}
{| class="toccolours" style="float: right; margin: 0 0 1em 1em; width: 20em; font-size: 90%; clear:right;" cellspacing="5"
|-
! colspan="2" style="text-align: center; font-size: larger;" | '''Serono'''
|-
| colspan="2" style="padding: 1em 0; text-align: center;" | [[Image:Serono logo.gif]]
|- style="vertical-align: top; text-align: left;"
| '''[[:category:types of companies|Type]]'''
| Stock corporation
|- style="vertical-align: top; text-align: left;"
| '''[[wiktionary:foundation|Founded]]'''
| 1906
|- style="vertical-align: top; text-align: left;"
|'''Location'''
| [[Geneva, Switzerland]] (Headquarters)
|- style="vertical-align: top; text-align: left;"
|'''Key people'''
| [[Ernesto Bertarelli]]<br/><small>CEO and Vice Chairman of the Board</small>
|- style="vertical-align: top; text-align: left;"
|'''[[Industry]]'''
| [[Biotechnology]] / [[Pharmaceutical company|Pharmaceutical]]
|- style="vertical-align: top; text-align: left;"
|'''[[Product (business)|Key Products]]'''
| Rebif, Gonal-f, Luveris, Ovidrel/Ovitrelle, Serostim, Saizen, Zorbtive and Raptiva
|- style="vertical-align: top; text-align: left;"
|'''[[Revenue]]'''
| USD ~2.5 billion (2005)
|- style="vertical-align: top; text-align: left;"
|'''[[Website]]'''
| http://www.serono.com
|}
'''Serono''' is a [[biotechnology]] [[company (law)|company]] headquartered in [[Geneva]], [[Switzerland]]. The company was founded in [[1906]] in [[Italy]]. A key step in its development was the discovery of a method of extracting urinary [[gonadotropin]]s by Dr Piero Donini allowing the company to become a leader in the supplier of fertility medications, notably [[Pergonal]]. Serono was incorporated in [[1987]] and the holding company, Ares-Serono S.A., changed its name to Serono S.A. in May 2000.
Serono as a stand-alone company develops and markets [[pharmaceutical]]s in the fields of [[Wiktionary:Reproductive health|Reproductive Health]], [[Multiple Sclerosis]], Growth & [[Metabolism]] and [[Dermatology]]. It is a world-leader in the infertility market with an estimated market share of 60%, making it the third largest biotechnology company in the world. Serono's most important product accounted for 31.6% of the company's sales in 2004.
The eight biotechnology products are available in four core therapeutic areas: [[neurology]] for the treatment of relapsing forms of [[multiple sclerosis]], [[Wiktionary:Reproductive health|reproductive health]] for treatments of [[infertility]], [[dermatology]], where Serono has launched biologics in Europe for moderate-to-severe [[psoriasis]], and
growth and [[metabolism]] for treatments for HIV-associated wasting and growth deficiencies.
The Company also conducts research in [[oncology]] and [[autoimmune diseases]].
==Sale to Merck KGaA==
Serono was sold to [[Merck KGaA]] in Sept. 2006 for € 10,6 Billion; [[Merck KGaA]] paid CHF 1,100 for each share. The new entity, which merges Serono with Merck's Ethicals division, is called [[Merck-Serono|Merck Serono]]. Its headquarters is in Geneva, within the new Serono facilities. The US operations are planned to remain near Boston. The process of merging started in January 2007 after various business regulatory reviews and phases are complete. Until that time, Serono and Merck KGaA still operate as separate entities. The new, combined entity, [[Merck Serono]] is expected to equal the sizes of other large biotechs.
==Facilities==
Serono operates in 44 countries, with manufacturing facilities in eight countries and sales in over 90 countries. Main manufacturing sites are in Switzerland, Italy, Spain and France; a fifth facility in Israel was closed in 2004 owing to its obsolescence. Research and development facilities are maintained in [[Geneva, Switzerland]], [[Boston, Massachusetts|Boston, USA]], and [[Ivrea]], Italy. It employs over 4,750 people with worldwide revenues of USD 2,586.4 million (2005). It has eight biotechnology products on the market, and more than 25 ongoing preclinical and clinical development projects at the end of 2005.
Serono Headquarters and the Geneva research site will move to a brand new campus (Horizon Secheron) in the heart of Geneva during the fall of 2006.
==Fertility LifeLines==
Serono provides Fertility LifeLines as a free and confidential source of information to infertility patients. [http://www.fertilitylifelines.com]
==External links==
* [http://www.pharmaceutical-business-review.com/companyprofile.asp?guid=69DDE48B-45E8-4E05-B1ED-4901168492F2&alpha=s A Company Profile]
* [http://www.merck.de Merck KGaA corporate homepage]
* [http://www.piribo.com/publications/pharmaceutical_companies/serono/serono_pharmaceutical_company_intelligence_report.html Serono Pharmaceutical Company Intelligence]
==Notes==
# {{note|origin}} [http://www.serono.com/ir/pdf/form20F_2002.pdf 2002 Form 20-F]. Retrieved July 3, 2005.
# {{note|facilities}} [http://www.serono.com/ir/pdf/form20F_2004_.pdf 2004 Form 20-F]. Retrieved July 3, 2005.
==Selected Company Websites==
* [http://www.serono.at Austria]
* [http://www.serono-canada.com Canada]
* [http://www.serono.cz Czech Republic]
* [http://www.serono.fr France]
* [http://www.serono.de Germany]
* [http://www.serono.gr Greece]
* [http://www.serono.it Italy]
* [http://www.serono.co.il Israel]
* [http://www.serono.co.jp Japan]
* [http://www.serono.co.kr Korea]
* [http://www.serono.ch Switzerland]
* [http://www.serono.com.tw Taiwan]
* [http://www.seronousa.com USA]
==Complete Company Profile==
* [http://www.serono.com Serono's Global website]
'''Bold text'''
[[Category:Biotechnology companies]]
[[Category:Pharmaceutical companies]]
[[Category:Multinational companies]]
[[de:Serono]]
[[fr:Serono]]
[[it:Serono]]
[[no:Serono]]